VHL and DNA damage repair pathway alterations as potential clinical biomarkers for first-line TKIs in metastatic clear cell renal cell carcinomas.
Jiale ZhouJunyun WangWen KongJin ZhangXiaorong WuJiwei HuangJunhua ZhengYonghui ChenWei ZhaiWei XuePublished in: Cellular oncology (Dordrecht) (2022)
We found that patients with mccRCC harboring DDR and VHL alterations were more likely to benefit from first-line VEGF-TKI systemic therapy than patients with wild-type disease. In addition, we found that a three-cluster prognostic model based on gene expression can predict PFS and ORR, which was well-matched with activated TIL infiltration.
Keyphrases
- wild type
- dna damage
- gene expression
- clear cell
- single cell
- cell therapy
- small cell lung cancer
- dna methylation
- squamous cell carcinoma
- oxidative stress
- dna repair
- vascular endothelial growth factor
- tyrosine kinase
- endothelial cells
- high grade
- advanced non small cell lung cancer
- stem cells
- chronic myeloid leukemia
- mesenchymal stem cells
- epidermal growth factor receptor